Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age

Journal of Rheumatology

Volumn 32, Issue 10, 2005, Pages 1968-1974

  Ettinger, Mark P ^a,f   Felsenberg, Dieter ^b   Harris, Steven T ^c   Wasnich, Richard ^a   Skag, Arne ^d   Hiltbrunner, Valerie ^e   Wilson, Katie ^e   Schimmer, Ralph C ^e   Miller, Paul D ^e  

^a RADIANT RESEARCH   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Bergen Osteoporosesenter   (Norway)

^e CCBR   (United States)

^f Regional Osteoporosis Center   (United States)

Author keywords

Bisphosphonates; Elderly; Ibandronate; Tolerability osteoporosis

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANALGESIC AGENT; ANTACID AGENT; ANTICOAGULANT AGENT; ANTIPYRETIC AGENT; ANTIRHEUMATIC AGENT; ANTIULCER AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CREATININE; GAMMA GLUTAMYLTRANSFERASE; HISTAMINE H2 RECEPTOR AGONIST; IBANDRONIC ACID; NITROGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTON PUMP INHIBITOR; VITAMIN D;

ADULT; AGE; AGED; ARTHRALGIA; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM ULCER; DYSPEPSIA; ESOPHAGITIS; ESOPHAGUS STENOSIS; ESOPHAGUS ULCER; FEMALE; GASTRITIS; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HUMAN; INJURY; LIMB PAIN; MAJOR CLINICAL STUDY; MENOPAUSE; MORPHOMETRICS; MULTICENTER STUDY; NAUSEA; PANCYTOPENIA; PEPTIC ULCER BLEEDING; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RASH; STOMACH PAIN; STOMACH ULCER; SUPPLEMENTATION; UPPER GASTROINTESTINAL TRACT; VERTEBRA FRACTURE; VOMITING;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; UPPER GASTROINTESTINAL TRACT;

EID: 26444539825     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Melton LJ 3rd. Epidemiology worldwide. Endocrinol Metab Clin North Am 2003;32:1-13.
2. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997;7:390-406.
3. Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med 1991;151:2026-32.
4. Greendale GA, Barrett-Connor E, Ingles S, Haile R. Late physical and functional effects of osteoporotic fracture in women: the Rancho Bernardo Study. J Am Geriatr Soc 1995;43:955-61.
5. Srivastava M, Deal C. Osteoporosis in elderly: prevention and treatment. Clin Geriatr Med 2002;18:529-55.
6. Fink HA, Ensrud KE, Nelson DB, et al. Disability after clinical fracture in postmenopausal women with low bone density: the fracture intervention trial (FIT). Osteoporos Int 2003;14:69-76.
7. Aspray TJ, Prentice A, Cole TJ, Sawo Y, Reeve J, Francis RM. Low bone mineral content is common but osteoporotic fractures are rare in elderly rural Gambian women. J Bone Miner Res 1996;11:1019-25.
8. Melton LJ, Chrischilles EA, Cooper C, Lane AW, Riggs LB. How many women have osteoporosis. J Bone Miner Res 1993;7:1005-10.
9. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997;103:12S-17S.
10. Ettinger M. Aging bone and osteoporosis: strategies for preventing fractures in the elderly. Arch Intern Med 2003;163:2237-46.
11. Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2002;6:1-146.
12. Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the elderly: a world-wide projection; Osteoporos Int 1992;2:285-9.
13. Kane RL, Ouslander JG, Abrass I. Drug therapy. In: Kane RL, Ouslander JG, Abrass I, editors. Essentials of clinical geriatrics. 4th ed. New York: McGraw-Hill; 1999:379-411.
14. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5.
15. Stratton MA, Salinas RC. Medication management in the elderly. J Okla State Med Assoc 2003;96:116-22.
16. Williams CM. Using medications appropriately in older adults. Am Fam Physician 2002;66:1917-24.
17. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003;14:259-62.
18. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-16.
19. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-8.
20. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310.
21. Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307-35.
22. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Porras AG. Clinical pharmacology of alendronate sodium. Osteoporos Int 1993;3:S13-6.
23. Papapoulos SE. Bisphosphonates in the management of postmenopausal osteoporosis. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. 2nd ed. New York: Academic Press; 2001:631-49.
24. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21.
25. Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 1998;4:1377-82.
26. Delmas PD, Recker RR, Chesnut CH 3rd, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792-8.
27. Chesnut C, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9.
28. Adami S, Zamberlan N. Adverse effects of bisphosphonates. A comparative review. Drug Saf 1996;14:158-70.
29. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994;4:320-2.
30. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.
31. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91.
32. Data on file. F. Hoffmann-La Roche Ltd., Basel, Switzerland.
33. Barrett J, Worth E, Bauss F, Epstein S. Ibandronate: a clinical, pharmacological and pharmacokinetic update. J Clin Pharmacol 2004;44:951-65.